C-peptide vs hGHRH(1-40)OH
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and hGHRH(1-40)OH (Human growth hormone-releasing factor (1-40) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | hGHRH(1-40)OH |
|---|---|---|
| Category | Pain Management | Growth Hormone |
| Full Name | Connecting peptide (C-peptide) | Human growth hormone-releasing factor (1-40) hydroxyl |
| Molecular Weight | 3020.3 Da | N/A |
| Half-Life | ~20-30 min | 5-20 minutes |
| Amino Acids | 31 | 40 |
| Typical Dose | no approved analgesic dose|research-only | 1-2 mcg/kg |
| Route | IV|subQ | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 85 |
| Research Status | Pre-clinical | Clinical Research |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
hGHRH(1-40)OH Benefits
- ✓GH secretion research
- ✓fragment-activity comparison
- ✓receptor binding studies
- ✓axis physiology modeling
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
hGHRH(1-40)OH Dosing
1-2 mcg/kg SC or IV in acute research settings|single-bolus GH stimulation protocols|repeated low-dose administration in comparative studies
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
hGHRH(1-40)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠lightheadedness
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
hGHRH(1-40)OH
Human GHRF(1-40)OH has been studied to understand how truncation of the native hormone changes biological potency and half-life. It is a common research tool for mapping minimal active sequences within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.